Target intelligence / Profile preview

Solute carrier family 6 member 14 (SLC6A14)

Target
SLC6A14
Molecular classification
Transporter, Solute carrier
01

Overview

Solute carrier family 6 member 14 (SLC6A14), also known as the ATB0,+ transporter system, is a Na+/Cl--coupled, highly concentrative amino acid transporter. It is unique in its ability to transport 18 of the 20 proteinogenic amino acids, excluding only the acidic amino acids aspartate and glutamate. SLC6A14 is expressed at very low levels in normal tissues but is highly upregulated in various solid tumors, including colorectal, pancreatic, cervical, and estrogen receptor-positive breast cancers. In these malignancies, it serves as a critical nutrient hub, importing essential amino acids and glutamine to fuel rapid cell proliferation, activate the oncogenic mTOR signaling pathway, and support metabolic reprogramming. Consequently, SLC6A14 is an attractive therapeutic target for cancer therapy, where its pharmacological blockade (e.g., using alpha-methyl-L-tryptophan) induces amino acid starvation, inhibits mTOR, and triggers apoptosis in tumor cells. Additionally, due to its broad substrate specificity and high concentrative capacity, SLC6A14 is being utilized as a drug delivery system to shuttle amino acid-conjugated prodrugs directly into target cells.

Other names
ATB0,+ transporter systemAmino acid transporter ATB0+Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)System B(0+) amino acid transporterATB(0,+)S6A14
02

Mechanism of action

Inhibition of amino acid transport via blockade of the substrate-binding site, leading to intracellular amino acid starvation, suppression of mTOR signaling, and induction of autophagy and apoptosis. It also acts as a delivery channel for amino acid-conjugated prodrugs to enhance intracellular drug accumulation.

03

Biological functions

Amino acid transportNutrient uptakemTOR signaling activationCell growthMetabolic regulation
04

Disease associations

CancerObesityInflammatory bowel diseaseCrohn's diseaseUlcerative colitisCystic fibrosis
05

Safety considerations

Potential for systemic amino acid depletionAssociation of SLC6A14 deficiency with obesity and metabolic syndrome under high-fat diet conditionsImpaired epithelial repair in the airwaysAlterations in intestinal immune cell infiltration and local inflammation
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

SLC6A14 expression levelEstrogen receptor (ER) statusmTOR phosphorylation statusCXCL5 expression

Beyond the preview

Go deeper on Solute carrier family 6 member 14 (SLC6A14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 6 member 14 (SLC6A14).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call